Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.

Biotechnology

Pinteon Therapeutics

Pinteon Therapeutics' headquarters in Newton, MA, United States

Martin Jefson

Michael Ahlijanian

Larry Altstiel

Todd Kilbaugh

Westley Nolin

Kaj Blennow

Adam Boxer

Lawrence Golbe

Suzanne Hendrix

Kurt Brunden

Jason R. Dinges

Jeff Ives

Henrik Zetterberg

Howard Fillit

Cristina Sampaio

Lee Goldstein

Ramon Diaz-Arrastia

The Advisory Team at Pinteon Therapeutics consists of a group of experts who provide strategic guidance and insights to advance the development of the novel antibody targeting toxic tau. They leverage their extensive knowledge in neurology, clinical research, and regulatory affairs to inform decision-making, optimize clinical study designs, and ensure alignment with industry standards, ultimately aiming to enhance the therapeutic impact on patients with neurodegenerative diseases.

Advisory Team

The Leadership Team at Pinteon Therapeutics directs the strategic vision and operational execution of the company’s mission to develop innovative therapies for neurodegenerative diseases. Comprised of industry experts including the Chief Medical Officer and Chief Scientific Officer, the team collaborates on clinical development, funding initiatives, and partnership opportunities to ensure the advancement of their novel antibody therapy. Their collective expertise drives decision-making to enhance patient outcomes and promote the overall success of the organization's research and clinical goals.

Leadership Team

Pinteon Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

Pinteon Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

Related companies